Comment by rcdmd

I'm assuming you're referring to RATHL? RATHL attempted to show a treatment regimen was non-inferior to bleo, and didn't. The results are quite controversial, and bleo remains standard of care for many Hodgkin's cases. However, that may change with future trials and more data. Bleo is, as you say, truly a poison. It hurts a lot of people. But on balance, it saves lives better than the alternatives when appropriately used.